Scientists at the University of Cambridge have taken an important step in vaccine research after completing early-stage human trials of a vaccine designed with the help of artificial intelligence.
Working with biotechnology spin-out DIOSynVax, the researchers developed a “universal” coronavirus vaccine aimed at offering protection against a broad group of related viruses rather than a single strain.
Findings from the university showed that the initial trial involved 39 healthy volunteers and confirmed that the vaccine was safe, with no serious adverse effects recorded.
The vaccine targets Sarbeco coronaviruses, a family that includes the virus responsible for COVID-19, SARS, and other related animal viruses that could potentially infect humans in the future.
Researchers say the development signals a shift away from traditional vaccine design, which typically responds to individual virus outbreaks after they occur.
“This represents a fundamental new vaccine technology that could prevent future pandemics before they begin.”
The approach uses artificial intelligence to analyse shared genetic patterns across multiple viruses and design a “super-antigen” intended to trigger a wider immune response.
Lead scientist Professor Jonathan Heeney explained that the goal is to move vaccine development from a reactive system to a more proactive, future-focused approach.
“We’ve converted vaccine development from being reactive to being future proof. Our vaccines will continue to provide protection against viruses even as they mutate into new strains,” he said.
He added that this method could reduce the constant cycle of updating vaccines to match emerging variants.
The trial vaccine was delivered in clinical centres in Southampton and Cambridge using a needle-free injection system.
Early results showed that participants developed immune responses not only to known coronaviruses but also to related animal viruses that have not yet infected humans.
Professor Saul Faust, the trial’s lead investigator, said the findings suggest the possibility of developing vaccines that can offer protection against future outbreaks before they begin.
He noted that further large-scale trials are still required to confirm effectiveness across a wider population.
The study, funded by Innovate UK, represents one of the first human tests of an AI-designed vaccine and could open the door to similar breakthroughs targeting other virus families such as influenza and Ebola.
